Xeris Biopharma Holdings, INC 10-Q quarterly reports

Xeris Biopharma Holdings, Inc. announced a 33.1% increase in total revenue for the six months ended June 30, 2026, driven by significant growth in Recorlev, though a substantial loss on debt extinguishment impacted net results.

Xeris Biopharma Holdings, Inc. announced its first quarter 2026 financial results, showcasing significant revenue growth driven by Recorlev, while managing operational expenses and focusing on pipeline development.

Xeris Biopharma Holdings, Inc. reported a significant increase in total revenue and a shift to positive net income for the third quarter of 2025, driven by robust Recorlev sales.

Xeris Biopharma Holdings, Inc. reported a significant reduction in net loss and strong revenue growth for the second quarter and first half of 2025, driven by increased sales of Recorlev and Gvoke.

Xeris Biopharma's Q1 2025 shows revenue growth driven by key products, with a continued focus on commercialization and pipeline development.

Xeris Biopharma's Q3 2024 results show revenue growth driven by Gvoke and Recorlev, alongside continued investment in their pipeline, particularly XP-8121.

Xeris Biopharma's Q2 2024 results show a 26.5% increase in total revenue compared to Q2 2023, driven primarily by strong growth in Recorlev sales.

Xeris Biopharma's first quarter of 2024 saw a revenue increase driven by Recorlev sales, alongside a debt refinancing to extend maturities.